Posted by Michael Wonder on 21 Jan 2021
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
21 January 2021 - NICE has published its final appraisal determination recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis.
The final appraisal determination means that the daily oral pill will now be available on the NHS in England for the treatment of eligible adults patients with moderate to severe active rheumatoid arthritis.
